Search

Your search keyword '"Geyer, Mark B."' showing total 276 results
Start Over Author "Geyer, Mark B."
276 results on '"Geyer, Mark B."'

2. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients.

Author

Mahmood, Syed S, Riedell, Peter A, Feldman, Stephanie, George, Gina, Sansoterra, Stephen A, Althaus, Thomas, Rehman, Mahin, Mead, Elena, Liu, Jennifer E, Devereux, Richard B, Weinsaft, Jonathan W, Kim, Jiwon, Balkan, Lauren, Barbar, Tarek, Lee Chuy, Katherine, Harchandani, Bhisham, Perales, Miguel-Angel, Geyer, Mark B, Park, Jae H, Palomba, M Lia, Shouval, Roni, Tomas, Ana A, Shah, Gunjan L, Yang, Eric H, Gaut, Daria L, Rothberg, Michael V, Horn, Evelyn M, Leonard, John P, Van Besien, Koen, Frigault, Matthew J, Chen, Zhengming, Mehrotra, Bhoomi, Neilan, Tomas G, and Steingart, Richard M

Abstract

Chimeric antigen receptor T-cell therapy (CAR-T) harnesses a patient's immune system to target cancer. There are sparse existing data characterizing death outcomes after CAR-T-related cardiotoxicity. This study examines the association between CAR-T-related severe cardiovascular events (SCE) and mortality.From a multi-centre registry of 202 patients receiving anti-CD19 CAR-T, covariates including standard baseline cardiovascular and cancer parameters and biomarkers were collected. Severe cardiovascular events were defined as a composite of heart failure, cardiogenic shock, or myocardial infarction. Thirty-three patients experienced SCE, and 108 patients died during a median follow-up of 297 (interquartile range 104-647) days. Those that did and did not die after CAR-T were similar in age, sex, and prior anthracycline use. Those who died had higher peak interleukin (IL)-6 and ferritin levels after CAR-T infusion, and those who experienced SCE had higher peak IL-6, C-reactive protein (CRP), ferritin, and troponin levels. The day-100 and 1-year Kaplan-Meier overall mortality estimates were 18% and 43%, respectively, while the non-relapse mortality (NRM) cumulative incidence rates were 3.5% and 6.7%, respectively. In a Cox model, SCE occurrence following CAR-T was independently associated with increased overall mortality risk [hazard ratio (HR) 2.8, 95% confidence interval (CI) 1.6-4.7] after adjusting for age, cancer type and burden, anthracycline use, cytokine release syndrome grade ≥ 2, pre-existing heart failure, hypertension, and African American ancestry; SCEs were independently associated with increased NRM (HR 3.5, 95% CI 1.4-8.8) after adjusting for cancer burden.Chimeric antigen receptor T-cell therapy recipients who experience SCE have higher overall mortality and NRM and higher peak levels of IL-6, CRP, ferritin, and troponin.

Published
2023

5. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results

Author

Mauro, Michael J., Hughes, Timothy P., Kim, Dong-Wook, Rea, Delphine, Cortes, Jorge E., Hochhaus, Andreas, Sasaki, Koji, Breccia, Massimo, Talpaz, Moshe, Ottmann, Oliver, Minami, Hironobu, Goh, Yeow Tee, DeAngelo, Daniel J., Heinrich, Michael C., Gómez-García de Soria, Valle, le Coutre, Philipp, Mahon, Francois-Xavier, Janssen, Jeroen J. W. M., Deininger, Michael, Shanmuganathan, Naranie, Geyer, Mark B., Cacciatore, Silvia, Polydoros, Fotis, Agrawal, Nithya, Hoch, Matthias, and Lang, Fabian

Published
2023
Full Text
View/download PDF

7. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia

Author

McCarter, Joseph G. W., Nemirovsky, David, Famulare, Christopher A., Farnoud, Noushin, Mohanty, Abhinita S., Stone-Molloy, Zoe S., Chervin, Jordan, Ball, Brian J., Epstein-Peterson, Zachary D., Arcila, Maria E., Stonestrom, Aaron J., Dunbar, Andrew, Cai, Sheng F., Glass, Jacob L., Geyer, Mark B., Rampal, Raajit K., Berman, Ellin, Abdel-Wahab, Omar I., Stein, Eytan M., Tallman, Martin S., Levine, Ross L., Goldberg, Aaron D., Papaemmanuil, Elli, Zhang, Yanming, Roshal, Mikhail, Derkach, Andriy, and Xiao, Wenbin

Published
2023
Full Text
View/download PDF

9. HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML.

Author

Chin, Kuo-Kai, Derkach, Andriy, Famulare, Christopher, Gupta, Gaurav K., Borge, P. Dayand, Geyer, Mark B., Goldberg, Aaron D., Haque, Tamanna, Park, Jae H., Roeker, Lindsey E., Tallman, Martin S., Stahl, Maximilian, and Stein, Eytan M.

Subjects
ACUTE myeloid leukemia, EMERGENCY room visits, FEBRILE neutropenia, INDUCTION chemotherapy, OVERALL survival
Abstract

Hypomethylating agents (HMA) and venetoclax (VEN) are commonly used in patients with IDH-mutated (IDHm) acute myeloid leukemia (AML) ineligible for induction chemotherapy. While prior studies demonstrated high response and survival rates with HMA/VEN in IDHm AML, the impact of treatment modifications in real-world settings is unclear. We retrospectively reviewed 89 IDHm AML patients treated with HMA/VEN from January 2018 to June 2023. CR/CRi rates were 76% in newly diagnosed (ND) and 55% in relapsed/refractory (R/R) patients, and median overall survival was 29.2 months (ND) and 17.1 months (R/R), respectively. Treatment modifications were common. Early VEN reductions were associated with lower response rates but not worse survival. Prolonged cycles were not associated with worse response rates or survival. Significant neutropenia and ED visits or unplanned hospitalizations were considerable before and after CR/CRi, though febrile neutropenia decreased afterward. HMA/VEN is efficacious, with treatment modifications not affecting survival, though long-term toxicities are notable. [ABSTRACT FROM AUTHOR]

Published
2025
Full Text
View/download PDF

10. The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia.

Author

Hochberg, Jessica, Zahler, Stacey, Geyer, Mark B, Chen, Nan, Krajewski, Jennifer, Harrison, Lauren, Militano, Olga, Ozkaynak, M Fevzi, Cheerva, Alexandra C, Talano, Julie, Moore, Theodore B, Gillio, Alfred P, Walters, Mark C, Baxter-Lowe, Lee Ann, Hamby, Carl, and Cairo, Mitchell S

Subjects
Humans, Leukemia, Acute Disease, Cytarabine, Antineoplastic Combined Chemotherapy Protocols, Myeloablative Agonists, Treatment Outcome, Transplantation Conditioning, Whole-Body Irradiation, Hematopoietic Stem Cell Transplantation, Transplantation, Homologous, Adolescent, Child, Child, Preschool, Infant, Female, Male, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Young Adult, Clofarabine, Immunology, Clinical Sciences, Oncology and Carcinogenesis
Abstract

Acute leukemias in children with CR3, refractory relapse, or induction failure (IF) have a poor prognosis. Clofarabine has single agent activity in relapsed leukemia and synergy with cytarabine. We sought to determine the safety and overall survival in a Phase I/II trial of conditioning with clofarabine (doses 40 - 52 mg/m2), cytarabine 1000 mg/m2, and 1200 cGy TBI followed by alloSCT in children, adolescents, and young adults with poor-risk leukemia. Thirty-seven patients; Age 12 years (1-22 years); ALL/AML: 34:3 (18 IF, 10 CR3, 13 refractory relapse); 15 related, 22 unrelated donors. Probabilities of neutrophil, platelet engraftment, acute GvHD, and chronic GvHD were 94%, 84%, 49%, and 30%, respectively. Probability of day 100 TRM was 8.1%. 2-year EFS (event free survival) and OS (overall survival) were 38.6% (CI95: 23-54%), and 41.3% (CI95: 25-57%). Multivariate analysis demonstrated overt disease at time of transplant (relative risk (RR) 3.65, CI95: 1.35-9.89, P = 0.011) and umbilical cord blood source (RR 2.17, CI95: 1.33-4.15, P = 0.019) to be predictors of worse EFS/OS. This novel myeloablative conditioning regimen followed by alloSCT is safe and well tolerated in CAYA with very poor-risk ALL or AML. Further investigation in CAYA with better risk ALL and AML undergoing alloSCT is warranted.

Published
2019

12. A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas

Author

Moskowitz, Alison J., Ghione, Paola, Jacobsen, Eric, Ruan, Jia, Schatz, Jonathan H., Noor, Sarah, Myskowski, Patricia, Vardhana, Santosha, Ganesan, Nivetha, Hancock, Helen, Davey, Theresa, Perez, Leslie, Ryu, Sunyoung, Santarosa, Alayna, Dowd, Jack, Obadi, Obadi, Pomerantz, Lauren, Yi, Nancy, Sohail, Samia, Galasso, Natasha, Neuman, Rachel, Liotta, Brielle, Blouin, William, Baik, Jeeyeon, Geyer, Mark B., Noy, Ariela, Straus, David, Kumar, Priyadarshini, Dogan, Ahmet, Hollmann, Travis, Drill, Esther, Rademaker, Jurgen, Schoder, Heiko, Inghirami, Giorgio, Weinstock, David M., and Horwitz, Steven M.

Published
2021
Full Text
View/download PDF

13. Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing

Author

Wang, Xiuyan, Borquez-Ojeda, Oriana, Stefanski, Jolanta, Du, Fang, Qu, Jinrong, Chaudhari, Jagrutiben, Thummar, Keyur, Zhu, Mingzhu, Shen, Ling-bo, Hall, Melanie, Gautam, Paridhi, Wang, Yongzeng, Sénéchal, Brigitte, Sikder, Devanjan, Adusumilli, Prasad S., Brentjens, Renier J., Curran, Kevin, Geyer, Mark B., Mailankhody, Sham, O’Cearbhaill, Roisin, Park, Jae H., Sauter, Craig, Slovin, Susan, Smith, Eric L., and Rivière, Isabelle

Published
2021
Full Text
View/download PDF

15. Outcomes of COVID-19 in patients with CLL: a multicenter international experience

Author

Mato, Anthony R., Roeker, Lindsey E., Lamanna, Nicole, Allan, John N., Leslie, Lori, Pagel, John M., Patel, Krish, Osterborg, Anders, Wojenski, Daniel, Kamdar, Manali, Huntington, Scott F., Davids, Matthew S., Brown, Jennifer R., Antic, Darko, Jacobs, Ryan, Ahn, Inhye E., Pu, Jeffrey, Isaac, Krista M., Barr, Paul M., Ujjani, Chaitra S., Geyer, Mark B., Berman, Ellin, Zelenetz, Andrew D., Malakhov, Nikita, Furman, Richard R., Koropsak, Michael, Bailey, Neil, Hanson, Lotta, Perini, Guilherme F., Ma, Shuo, Ryan, Christine E., Wiestner, Adrian, Portell, Craig A., Shadman, Mazyar, Chong, Elise A., Brander, Danielle M., Sundaram, Suchitra, Seddon, Amanda N., Seymour, Erlene, Patel, Meera, Martinez-Calle, Nicolas, Munir, Talha, Walewska, Renata, Broom, Angus, Walter, Harriet, El-Sharkawi, Dima, Parry, Helen, Wilson, Matthew R., Patten, Piers E.M., Hernández-Rivas, José-Ángel, Miras, Fatima, Fernández Escalada, Noemi, Ghione, Paola, Nabhan, Chadi, Lebowitz, Sonia, Bhavsar, Erica, López-Jiménez, Javier, Naya, Daniel, Garcia-Marco, Jose Antonio, Skånland, Sigrid S., Cordoba, Raul, and Eyre, Toby A.

Published
2020
Full Text
View/download PDF

16. Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents

Author

Roeker, Lindsey E., Dreger, Peter, Brown, Jennifer R., Lahoud, Oscar B., Eyre, Toby A., Brander, Danielle M., Skarbnik, Alan, Coombs, Catherine C., Kim, Haesook T., Davids, Matthew, Manchini, Steven T., George, Gemlyn, Shah, Nirav, Voorhees, Timothy J., Orchard, Kim H., Walter, Harriet S., Arumainathan, Arvind K., Sitlinger, Andrea, Park, Jae H., Geyer, Mark B., Zelenetz, Andrew D., Sauter, Craig S., Giralt, Sergio A., Perales, Miguel-Angel, and Mato, Anthony R.

Published
2020
Full Text
View/download PDF

17. Multilineage involvement in KMT2A‐rearranged B acute lymphoblastic leukaemia: cell‐of‐origin, biology, and clinical implications

Author

Aypar, Umut, primary, Dilip, Deepika, additional, Gadde, Ramya, additional, Londono, Dory M, additional, Liu, Ying, additional, Gao, Qi, additional, Geyer, Mark B, additional, Derkach, Andriy, additional, Zhang, Yanming, additional, Glass, Jacob L, additional, Roshal, Mikhail, additional, and Xiao, Wenbin, additional

Published
2024
Full Text
View/download PDF

20. Low-Dose Targeted Radioimmunotherapy (Iomab-ACT) Achieves Lymphocyte and Monocyte Depletion Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed of Refractory B-Cell ALL or DLBCL with Minimal CRS and Icans

Author

Geyer, Mark B., primary, Hosszu, Kinga, additional, Senechal, Brigitte, additional, McAvoy, Devin, additional, Vusirikala, Madhuri, additional, Spross, Jennifer, additional, van der Touw, William, additional, Syed, Umar, additional, Desai, Avinash, additional, Cadzin, Briana, additional, Hieronymi, Sophie, additional, and Pandit-Taskar, Neeta, additional

Published
2024
Full Text
View/download PDF

21. Atrial arrhythmias following CAR‐chimeric antigen receptor T‐cell therapy: Incidence, risk factors and biomarker profile.

Author

Shouval, Roni, Goldman, Adam, Flynn, Jessica R., El‐Moghraby, Ahmed, Rehman, Mahin, Devlin, Sean M., Corona, Magdalena, Landego, Ivan, Lin, Richard J., Scordo, Michael, Raj, Sandeep S., Giralt, Sergio A., Palomba, M. Lia, Dahi, Parastoo B., Walji, Moneeza, Salles, Gilles, Nath, Karthik, Geyer, Mark B., Park, Jae H., and Fein, Joshua A.

Subjects
DISEASE risk factors, CHIMERIC antigen receptors, CYTOKINE release syndrome, ANTIGEN receptors, ATRIAL arrhythmias, CARDIOTOXICITY
Abstract

Summary: Recent reports have raised concerns about the association of chimeric antigen receptor T cell (CAR‐T) with non‐negligible cardiotoxicity, particularly atrial arrhythmias. First, we conducted a pharmacovigilance study to assess the reporting of atrial arrhythmias following CD19‐directed CAR‐T. Subsequently, to determine the incidence, risk factors and outcomes of atrial arrhythmias post‐CAR‐T, we compiled a retrospective single‐centre cohort of non‐Hodgkin lymphoma patients. Only commercial CAR‐T products were considered. Atrial arrhythmias were nearly fourfold more likely to be reported after CAR‐T therapy compared to all other cancer patients in the FAERS (adjusted ROR = 3.76 [95% CI 2.67–5.29]). Of the 236 patients in our institutional cohort, 23 (10%) developed atrial arrhythmias post‐CAR‐T, including 12 de novo arrhythmias, with most (83%) requiring medical intervention. Atrial arrhythmias frequently co‐occurred with cytokine release syndrome and were associated with higher post‐CAR‐T infusion peak levels of IL‐10, TNF‐alpha and LDH, and lower trough levels of fibrinogen. In a multivariable analysis, risk factors for atrial arrhythmia were history of atrial arrhythmia (OR = 6.80 [2.39–19.6]) and using CAR‐T product with a CD28‐costimulatory domain (OR = 5.17 [1.72–18.6]). Atrial arrhythmias following CD19‐CAR‐T therapy are prevalent and associated with elevated inflammatory biomarkers, a history of atrial arrhythmia and the use of a CAR‐T product with a CD28 costimulatory domain. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

22. Acute Febrile Neutrophilic Dermatosis (Sweet Syndrome) in Acute Myeloid Leukemia Patients: A 28-Year Institutional Experience.

Author

Cowen, Emily A., Barrios, Dulce M., Pulitzer, Melissa P., Moy, Andrea P., Dusza, Stephen W., De Wolf, Susan, Geyer, Mark B., and Markova, Alina

Subjects
SWEET'S syndrome, CHRONIC leukemia, ACUTE myeloid leukemia, MYELODYSPLASTIC syndromes, MYELOPROLIFERATIVE neoplasms
Abstract

Introduction: Sweet syndrome (SS) is well known to be associated with underlying hematologic malignancies. The incidence and qualities of SS among novel targeted therapies for acute myeloid leukemia (AML) have not yet been described. Methods: Through retrospective review of 19,432 patients diagnosed with acute/chronic leukemia or myelodysplastic syndromes/myeloproliferative neoplasms (MDS+/−MPN) over 28 years, we calculated the incidence of SS in the setting of select hematologic malignancies and described the clinicopathologic characteristics of SS in patients with onset of SS after initiation of novel AML-targeted therapies. Results: Overall incidence of SS was 0.36% (95% CI: 0.27–0.45%), which was significantly higher among patients with AML (50/5,248, 0.94%; 95% CI: 0.71–1.25%). Nine AML patients were on 4 classes of novel targeted treatments – IDH1/2 inhibitor alone, FLT3 inhibitor, IDH2 and DOT1L inhibitor, and anti-CD33 therapy. In therapies inducing myeloid blast differentiation, SS occurred at later onset following treatment. Conclusions: In AML patients with fever and unusual skin lesions, physicians may consider SS earlier, which may shorten time to diagnosis. Future assessments of SS among patients treated with novel therapies for AML and molecular studies of biopsies may help further explain this dermatologic adverse event with earlier diagnosis and management of neutrophilic dermatoses in these patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

25. Acute myeloid leukemia with mixed phenotype is characterized by stemness transcriptomic signatures and limited lineage plasticity

Author

Galera, Pallavi, primary, Dilip, Deepika, additional, Derkach, Andriy, additional, Chan, Alexander, additional, Zhang, Yanming, additional, Persuad, Sonali, additional, Mishera, Tanmay, additional, Liu, Ying, additional, Famulare, Christopher, additional, Gao, Qi, additional, Mata, Douglas A., additional, Arcila, Maria, additional, Geyer, Mark B., additional, Stein, Eytan, additional, Dogan, Ahmet, additional, Levine, Ross L., additional, Roshal, Mikhail, additional, Glass, Jacob, additional, and Xiao, Wenbin, additional

Published
2023
Full Text
View/download PDF

26. Hairy Cell Leukemia

Author

Geyer, Mark B., primary, Abdel-Wahab, Omar, additional, Tallman, Martin S., additional, and Park, Jae H., additional

Published
2020
Full Text
View/download PDF

27. Contributors

Author

Abbruzzese, James L., primary, Abdel-Wahab, Omar, additional, Abou-Alfa, Ghassan K., additional, Abrahm, Janet L., additional, Abrams, Jeffrey S., additional, Abramson, Jeremy S., additional, Aisner, Dara L., additional, Alonso-Basanta, Michelle, additional, Anampa, Jesus, additional, Anderson, Megan E., additional, Antonarakis, Emmanuel S., additional, Aplenc, Richard, additional, Appelbaum, Frederick R., additional, Araujo, Luiz H., additional, Asban, Ammar, additional, Ashwood, Edward, additional, Awan, Farrukh T., additional, Aylward, Juliet L., additional, Balar, Arjun V., additional, Balentine, Courtney J., additional, Barta, Stefan K., additional, Bartlett, Nancy, additional, Basen-Engquist, Karen, additional, Beaupin, Lynda Kwon, additional, Berkowitz, Ross S., additional, Berry, Donald A., additional, Bevers, Therese, additional, Boggess, John F., additional, Brahmer, Julie R., additional, Brown, Janet, additional, Brown, Karen, additional, Brown, Powel, additional, Browner, Ilene, additional, Bunn, Paul A., additional, Burns, William R., additional, Byrd, John C., additional, Cadoo, Karen, additional, Carbone, David P., additional, Carter, H. Ballentine, additional, Castillo, Jorge J., additional, Chang, Alfred E., additional, Chang, Eric, additional, Chanock, Stephen J., additional, Chapuy, Claudia I., additional, Chauhan, Vikash P., additional, Chen, Herbert, additional, Chen, Ronald C., additional, Cheung, Nai-Kong V., additional, Choe, Jennifer H., additional, Christian, Michaele C., additional, Cinciripini, Paul M., additional, Clarke, Michael F., additional, Coleman, Robert E., additional, Coleman, Robert L., additional, Coletta, Adriana M., additional, Collins, Jerry M., additional, Connors, Jean M., additional, Cools, Michael, additional, Coombes, Kevin R., additional, Cortes, Jorge, additional, Costa, Mauro W., additional, Covey, Anne, additional, Cowan, Kenneth H., additional, Crane, Christopher H., additional, Crawford, Jeffrey, additional, Crooks, Kristy, additional, Culkin, Daniel J., additional, Czito, Brian G., additional, Dalerba, Piero, additional, Dalmau, Josep, additional, Dang, Mai, additional, D'Angelica, Michael, additional, Davies, Kurtis D., additional, Davis, Myrtle, additional, Dea, Nicolas, additional, De Jesus-Acosta, Ana, additional, DeMarzo, Angelo M., additional, DeWeese, Theodore L., additional, Diehn, Maximilian, additional, Digumarthy, Subba R., additional, Dispenzieri, Angela, additional, Do, Khanh T., additional, Dobrenkov, Konstantin, additional, Dome, Jeffrey S., additional, Doroshow, James H., additional, Dorsey, Jay F., additional, Dubard-Gault, Marianne, additional, DuBois, Steven G., additional, Duda, Dan G., additional, Dunlop, Malcolm, additional, Duska, Linda R., additional, Duvic, Madeleine, additional, El Dika, Imane, additional, El-Serag, Hashem, additional, Engelmann, Jeffrey M., additional, Ettinger, David S., additional, Fashoyin-Aje, Lola A., additional, Fearon, Eric R., additional, Ford, James M., additional, Franklin, Wilbur A., additional, Freer, Phoebe E., additional, Freidlin, Boris, additional, Freifeld, Alison G., additional, Friedlander, Terence W., additional, Friedman, Debra L., additional, Fuller, Arian F., additional, Galluzzi, Lorenzo, additional, Gebhardt, Mark C., additional, George, Daniel J., additional, Geyer, Mark B., additional, Giaccia, Amato J., additional, Gilbert, Mark R., additional, Goldner, Whitney, additional, Goldstein, Donald P., additional, Goodman, Annekathryn, additional, Goodman, Karyn A., additional, Gordon, Kathleen, additional, Graeff-Armas, Laura, additional, Greenstein, Alexander J., additional, Grossman, Stuart A., additional, Grupp, Stephan, additional, Gupta, Arjun, additional, Haider, Irfanullah, additional, Haigentz, Missak, additional, Hainsworth, John D., additional, Haithcock, Benjamin E., additional, Hallemeier, Christopher L., additional, Hanash, Samir, additional, Hanrahan, Aphrothiti J., additional, Harding, James, additional, Harrison, Michael R., additional, Hasham, Muneer G., additional, Hawk, Ernest, additional, Hayman, Jonathan, additional, Heinlen, Jonathan E., additional, Henry, N. Lynn, additional, Herman, Joseph, additional, Hobbs, Brian P., additional, Holen, Ingunn, additional, Horn, Leora, additional, Horowitz, Neil S., additional, Horwitz, Steven M., additional, Houghton, Odette, additional, Howard, Scott C., additional, Hudis, Clifford A., additional, Hunger, Stephen P., additional, Hurria, Arti, additional, Ilson, David H., additional, Im, Annie, additional, Iyer, Gopa, additional, Jaffee, Elizabeth M., additional, Jagsi, Reshma, additional, Jain, Rakesh K., additional, Jarnagin, William, additional, Jatoi, Aminah, additional, Jhingran, Anuja, additional, Johnson, David H., additional, Johnston, Brian, additional, Johnston, Patrick G., additional, Judy, Kevin D., additional, Kachnic, Lisa A., additional, Kaidar-Person, Orit, additional, Kalva, Sanjeeva, additional, Kamin, Deborah Y., additional, Kantarjian, Hagop, additional, Karakousis, Giorgos, additional, Karam-Hage, Maher, additional, Kaskas, Nadine M., additional, Kastan, Michael B., additional, Katabi, Nora, additional, Kaul, Daniel R., additional, Kelley, Scott R., additional, Kemeny, Nancy, additional, Kent, Erin E., additional, Kepp, Oliver, additional, Khagi, Simon, additional, Kilgore, Joshua E., additional, Kim, D. Nathan, additional, Kleinschmidt-DeMasters, Bette K., additional, Korn, Edward L., additional, Kroemer, Guido, additional, Ku, Geoffrey Y., additional, Kummar, Shivaani, additional, Ky, Bonnie, additional, Laheru, Daniel A., additional, Lambert, Paul F., additional, Lawler, Mark, additional, Le-Rademacher, Jennifer G., additional, Lee, John Y.K., additional, Lee, Nancy Y., additional, Lee, Susanna L., additional, Leeman, Jonathan E., additional, Linkermann, Andreas, additional, Liu, Jinsong, additional, Lo, Simon, additional, Locasale, Jason W., additional, Loprinzi, Charles L., additional, Lowery, Maeve, additional, Ludwig, Emmy, additional, Lunning, Matthew A., additional, Lustig, Robert A., additional, Machtay, Mitchell, additional, Mackall, Crystal, additional, Mahvi, David A., additional, Mahvi, David M., additional, Maity, Amit, additional, Majithia, Neil, additional, Malumbres, Marcos, additional, Maresso, Karen Colbert, additional, Martin, John D., additional, Matsuo, Koji, additional, Matthews, Natalie H., additional, Mauro, Lauren, additional, Mayer, R. Samuel, additional, McCaskill-Stevens, Worta, additional, McNamara, Megan A., additional, Mehta-Shah, Neha, additional, Merritt, Robert E., additional, Milowsky, Matthew I., additional, Minasian, Lori M., additional, Mitchell, Tara C., additional, Mitsis, Demytra, additional, Mollica, Michelle, additional, Mooney, Margaret, additional, Moustafa, Farah, additional, Nabati, Lida, additional, Naidoo, Jarushka, additional, Narang, Amol, additional, Nelson, Heidi, additional, Nelson, William G., additional, Nesbit, Suzanne, additional, Niglas, Mark, additional, O'Connor, Tracey, additional, Offit, Kenneth, additional, Onciu, Mihaela, additional, O’Reilly, Eileen M., additional, Ostrander, Elaine A., additional, Pappas-Taffer, Lisa, additional, Pardoll, Drew, additional, Park, Jae H., additional, Patel, Anery, additional, Patel, Anish J., additional, Patierno, Steven R., additional, Pavletic, Steven Z., additional, Phillips, Peter C., additional, Post, Miriam D., additional, Pruitt, Amy A., additional, Querfeld, Christiane, additional, Rabius, Vance A., additional, Rajkumar, S. Vincent, additional, Ramadan, Mohammad O., additional, Rankin, Erinn B., additional, Reddy, Sushanth, additional, Reid, Michael A., additional, Reznik, Scott, additional, Rizack, Tina, additional, Robinson, Jason D., additional, Robinson-Bostom, Leslie, additional, Rodriguez-Galindo, Carlos, additional, Romesser, Paul B., additional, Rosen, Steven T., additional, Rosenfeld, Myrna R., additional, Rosenthal, Nadia, additional, Ross, Meredith, additional, Rowland, Julia H., additional, Russell, Anthony H., additional, Sabel, Michael S., additional, Sahgal, Arjun, additional, Salinas, Ryan D., additional, Salo-Mullen, Erin E., additional, Salto-Tellez, Manuel, additional, Sanderson, Sydney M., additional, Sandlund, John T., additional, Santana, Victor M., additional, Savage, Michelle, additional, Schreiber, Eric C., additional, Schuchter, Lynn, additional, Schultz, Liora, additional, Seiden, Michael V., additional, Sellers, Morgan M., additional, Shah, Payal D., additional, Shia, Jinru, additional, Shilo, Konstantin, additional, Small, Eric, additional, Smith, Angela B., additional, Snow, Stephen N., additional, Solit, David B., additional, Sood, Anil K., additional, Soto-Perez-de-Celis, Enrique, additional, Sparano, Joseph A., additional, Spiegelman, Vladimir S., additional, Spunt, Sheri L., additional, Stadler, Zsofia K., additional, Steensma, David P., additional, Stone, Richard M., additional, Stranne, Steven Kent, additional, Stratton, Kelly, additional, Sugden, Bill, additional, Swanson, Andrew M., additional, Tallman, Martin S., additional, Talmadge, James E., additional, Teachey, David T., additional, Teba, Catalina V., additional, Tefferi, Ayalew, additional, Teh, Bin Tean, additional, Teng, Joyce M.C., additional, Tepper, Joel E., additional, Thaker, Premal H., additional, Thrift, Aaron P., additional, Tran, Arthur-Quan, additional, Triska, Grace, additional, Trump, Donald, additional, Tsai, Kenneth, additional, Tseng, Chia-Lin, additional, Tseng, Diane, additional, Van Schaeybroeck, Sandra, additional, Van Tine, Brian A., additional, Vanness, Erin R., additional, Varadhachary, Gauri, additional, Varella-Garcia, Marileila, additional, Wahl, Richard L., additional, Walsh, Michael F., additional, Wang, Thomas, additional, Weiss, Jared, additional, Weissman, Irving L., additional, Westin, Shannon N., additional, White, Jeffrey D., additional, Wilson, Richard, additional, Wong, Richard J., additional, Wood, Gary S., additional, Xu, Yaohui G., additional, Xu-Welliver, Meng, additional, Yust-Katz, Shlomit, additional, Zagar, Timothy, additional, Zeman, Elaine M., additional, Zhang, Tian, additional, and Zwiebel, James A., additional

Published
2020
Full Text
View/download PDF

31. Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

32. Supplementary Data from BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy

Author

Smith, Eric L., primary, Mailankody, Sham, primary, Staehr, Mette, primary, Wang, Xiuyan, primary, Senechal, Brigitte, primary, Purdon, Terence J., primary, Daniyan, Anthony F., primary, Geyer, Mark B., primary, Goldberg, Aaron D., primary, Mead, Elena, primary, Santomasso, Bianca D., primary, Landa, Jonathan, primary, Rimner, Andreas, primary, Riviere, Isabelle, primary, Landgren, Ola, primary, and Brentjens, Renier J., primary

Published
2023
Full Text
View/download PDF

33. Biomarkers and cardiovascular outcomes in chimeric antigen receptor T-cell therapy recipients

Author

Mahmood, Syed S, primary, Riedell, Peter A, additional, Feldman, Stephanie, additional, George, Gina, additional, Sansoterra, Stephen A, additional, Althaus, Thomas, additional, Rehman, Mahin, additional, Mead, Elena, additional, Liu, Jennifer E, additional, Devereux, Richard B, additional, Weinsaft, Jonathan W, additional, Kim, Jiwon, additional, Balkan, Lauren, additional, Barbar, Tarek, additional, Lee Chuy, Katherine, additional, Harchandani, Bhisham, additional, Perales, Miguel-Angel, additional, Geyer, Mark B, additional, Park, Jae H, additional, Palomba, M Lia, additional, Shouval, Roni, additional, Tomas, Ana A, additional, Shah, Gunjan L, additional, Yang, Eric H, additional, Gaut, Daria L, additional, Rothberg, Michael V, additional, Horn, Evelyn M, additional, Leonard, John P, additional, Van Besien, Koen, additional, Frigault, Matthew J, additional, Chen, Zhengming, additional, Mehrotra, Bhoomi, additional, Neilan, Tomas G, additional, and Steingart, Richard M, additional

Published
2023
Full Text
View/download PDF

35. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia: an appraisal of the new WHO and IC classifications and ELN risk stratification

Author

McCarter, Joseph GW., primary, Nemirovsky, David, additional, Famulare, Christopher A., additional, Farnoud, Noushin, additional, Mohanty, Abhinita S., additional, Stone-Molloy, Zoe S., additional, Chervin, Jordan, additional, Ball, Brian J., additional, Epstein-Peterson, Zachary D., additional, Arcila, Maria E., additional, Stonestrom, Aaron J., additional, Dunbar, Andrew, additional, Cai, Sheng F., additional, Glass, Jacob L., additional, Geyer, Mark B., additional, Rampal, Raajit K., additional, Berman, Ellin, additional, Abdel-Wahab, Omar I., additional, Stein, Eytan M., additional, Tallman, Martin S., additional, Levine, Ross L., additional, Goldberg, Aaron D., additional, Papaemmanuil, Elli, additional, Zhang, Yanming, additional, Roshal, Mikhail, additional, Derkach, Andriy, additional, and Xiao, Wenbin, additional

Published
2022
Full Text
View/download PDF

37. An Ongoing Pilot Study of Targeted Radioimmunotherapy (131-I Apamistamab) Conditioning Prior to CD19-Targeted CAR T-Cell Therapy for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Author

Geyer, Mark B., primary, Cadzin, Briana, additional, Hosszu, Kinga, additional, Senechal, Brigitte, additional, Spross, Jennifer A., additional, Mark, Alexis, additional, Desai, Avinash, additional, Cathcart, Elizabeth R., additional, Palomba, M. Lia, additional, and Pandit-Taskar, Neeta, additional

Published
2022
Full Text
View/download PDF

38. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia

Author

Stahl, Maximilian, primary, Derkach, Andriy, additional, Farnoud, Noushin, additional, Bewersdorf, Jan Philipp, additional, Robinson, Troy, additional, Famulare, Christopher, additional, Cho, Christina, additional, Devlin, Sean, additional, Menghrajani, Kamal, additional, Patel, Minal A., additional, Cai, Sheng F., additional, Miles, Linde A., additional, Bowman, Robert L., additional, Geyer, Mark B., additional, Dunbar, Andrew, additional, Epstein‐Peterson, Zachary D., additional, McGovern, Erin, additional, Schulman, Jessica, additional, Glass, Jacob L., additional, Taylor, Justin, additional, Viny, Aaron D., additional, Stein, Eytan M., additional, Getta, Bartlomiej, additional, Arcila, Maria E., additional, Gao, Qi, additional, Barker, Juliet, additional, Shaffer, Brian C., additional, Papadopoulos, Esperanza B., additional, Gyurkocza, Boglarka, additional, Perales, Miguel‐Angel, additional, Abdel‐Wahab, Omar, additional, Levine, Ross L., additional, Giralt, Sergio A., additional, Zhang, Yanming, additional, Xiao, Wenbin, additional, Pai, Nidhi, additional, Papaemmanuil, Elli, additional, Tallman, Martin S., additional, Roshal, Mikhail, additional, and Goldberg, Aaron D., additional

Published
2022
Full Text
View/download PDF

39. Dermatologic adverse events in acute lymphocytic leukemia patients treated with bispecific T-cell engager blinatumomab.

Author

Parisi, Rose, Cowen, Emily A., Gu, Stephanie, Dusza, Stephen, Pulitzer, Melissa, Geyer, Mark B., King, Amber C., and Markova, Alina

Subjects
LYMPHOBLASTIC leukemia, ECZEMA, SEBORRHEIC dermatitis, T cells
Abstract

Patients with blinatumomab DAEs experience CRS, ICANS, and MRD-negative response as frequently as non-DAE patients. HT

CharacteristicAll patients on blinatumomab monotherapy (N = 45)Patients with DAE on blinatumomab monotherapya (N = 7)
Age, mean4 Fourteen patients on monotherapy had 18 DAEs; nine DAEs were determined to be unlikely related or unrelated to blinatumomab, three of these were irritant or allergic contact dermatitis to the infusion line securement antisepsis or dressings. [Extracted from the article]

Published
2023
Full Text
View/download PDF

41. Molecular predictors of immunophenotypic measurable residual disease clearance in acute myeloid leukemia.

Author

Stahl, Maximilian, Derkach, Andriy, Farnoud, Noushin, Bewersdorf, Jan Philipp, Robinson, Troy, Famulare, Christopher, Cho, Christina, Devlin, Sean, Menghrajani, Kamal, Patel, Minal A., Cai, Sheng F., Miles, Linde A., Bowman, Robert L., Geyer, Mark B., Dunbar, Andrew, Epstein‐Peterson, Zachary D., McGovern, Erin, Schulman, Jessica, Glass, Jacob L., and Taylor, Justin

Published
2023
Full Text
View/download PDF

42. Iomab with Adoptive Cellular Therapy (Iomab-ACT): A Pilot Study of 131-I Apamistamab Followed By CD19-Targeted CAR T-Cell Therapy for Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma

Author

Geyer, Mark B., primary, Cadzin, Briana, additional, Halton, Elizabeth, additional, Kane, Peter, additional, Senechal, Brigitte, additional, Geoghegan, Eileen M., additional, Reddy, Vijay, additional, Berger, Mark S., additional, Ludwig, Dale, additional, Pandit-Taskar, Neeta, additional, and Sauter, Craig S., additional

Published
2021
Full Text
View/download PDF

43. Molecular Predictors and Effectiveness of Measurable Residual Disease (MRD) Eradication with Chemotherapy and Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia

Author

Stahl, Maximilian, Derkach, Andriy, Famulare, Christopher, Cho, Christina, Devlin, Sean, Farnoud, Noushin, Menghrajani, Kamal, Patel, Minal A, Cai, Sheng F, Geyer, Mark B., Dunbar, Andrew, Epstein-Peterson, Zachary D., McGovern, Erin, Schulman, Jessica, Glass, Jacob L, Taylor, Justin, Viny, Aaron D, Stein, Eytan M., Getta, Bartlomiej, Arcila, Maria E., Levine, Ross L., Barker, Juliet, Shaffer, Brian C., Papadopoulos, Esperanza B., Gyurkocza, Boglarka, Perales, Miguel-Angel, Abdel-Wahab, Omar, Papaemmanuil, Elli, Giralt, Sergio A., Zhang, Yanming, Roshal, Mikhail, Tallman, Martin S., and Goldberg, Aaron D

Published
2020
Full Text
View/download PDF

44. Pilot Trial of Risk-Adapted Cyclophosphamide Intensity Based Conditioning and HLA Matched Sibling and Unrelated Cord Blood Stem Cell Transplantation in Newly Diagnosed Pediatric and Adolescent Recipients with Acquired Severe Aplastic Anemia

Author

McGuinn, Catherine, Geyer, Mark B., Jin, Zhezhen, Garvin, James H., Satwani, Prakash, Bradley, Brigid M., Bhatia, Monica, George, Diane, Duffy, Deirdre, Morris, Erin, van de Ven, Carmella, Schwartz, Joseph, Baxter-Lowe, Lee Ann, and Cairo, Mitchell S.

Published
2014
Full Text
View/download PDF

45. Defining Two Biologically and Clinically Distinct Groups in Acute Leukemia with a Mixed Phenotype

Author

Galera, Pallavi, Dilip, Deepika, Derkach, Andriy, Chan, Alexander, Zhang, Yanming, Persuad, Sonali, Mishra, Tanmay, Kramer, Kyle, Kathpalia, Mahak, Liu, Ying, Famulare, Christopher, Gao, Qi, Mata, Douglas A., Arcila, Maria, Geyer, Mark B., Stein, Eytan, Dogan, Ahmet, Roshal, Mikhail, Levine, Ross L., Glass, Jacob, and Xiao, Wenbin

Abstract

AML-MP and MPAL are biologically distinct despite sharing features of mixed phenotype.

Published
2025
Full Text
View/download PDF

46. Reduced Toxicity Conditioning and Allogeneic Hematopoietic Progenitor Cell Transplantation for Recessive Dystrophic Epidermolysis Bullosa

Author

Geyer, Mark B., Radhakrishnan, Kavita, Giller, Roger, Umegaki, Noriko, Harel, Sivan, Kiuru, Maija, Morel, Kimberly D., LeBoeuf, Nicole, Kandel, Jessica, Bruckner, Anna, Fabricatore, Sandra, Chen, Mei, Woodley, David, McGrath, John, Baxter-Lowe, LeeAnn, Uitto, Jouni, Christiano, Angela M., and Cairo, Mitchell S.

Published
2015
Full Text
View/download PDF

47. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality

Author

Stahl, Maximilian, primary, Narendra, Varun, additional, Jee, Justin, additional, Derkach, Andriy, additional, Maloy, Molly, additional, Geyer, Mark B., additional, Mato, Anthony R., additional, Roeker, Lindsey E., additional, Tallman, Martin S., additional, Shah, Gunjan L., additional, Daniyan, Anthony, additional, and Goldberg, Aaron D., additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results